Overexpression of cyclooxygenase-1 correlates with poor prognosis in renal cell carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 6, 2013, Pages 3729-3734

  Yu, Zu Hu ^a,b   Zhang, Qiang ^a,b   Wang, Ya Dong ^a,b   Chen, Jing ^a   Jiang, Zhi Mao ^a   Shi, Min ^a   Guo, Xi ^a   Qin, Jie ^a   Cui, Guang Hui ^a   Cai, Zhi Ming ^a   Gui, Yao Ting ^a   Lai, Yong Qing ^a  

^a PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Cyclooxygenase 1; Prognostic marker; Renal cell carcinoma

Indexed keywords

EID: 84882685032     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.6.3729     Document Type: Article

References (30)

1. Amin MB, Tamboli P, Javidan J, et al (2002). Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol, 26, 281-91.
2. Bao S, Ouyang G, Bai X, et al (2004). Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell, 5, 329-39.
3. Choi YD, Kim KS, Ryu S, et al (2007). Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma. J Korean Med Sci, 22, 305-10.
4. Daikoku T, Wang D, Tranguch S, et al (2005). Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res, 65, 3735-44.
5. Diamantopoulou K, Lazaris A, Mylona E, et al (2005). Cyclooxygenase-2 protein expression in relation to apoptotic potential and its prognostic significance in bladder urothelial carcinoma. Anticancer Res, 25, 4543-9.
6. Greene F BC, Fleming I, Fritz A, Haller D. 2002. AJCC: Cancer Staging Manual. New York: Springers-Verlag.
7. Gupta RA, Tejada LV, Tong BJ, et al (2003). Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res, 63, 906-11.
8. Hashimoto Y, Kondo Y, Kimura G, et al (2004). Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathology, 44, 353-9.
9. Hida T, Yatabe Y, Achiwa H, et al (1998). Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res, 58, 3761-4.
10. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics. CA Cancer J Clin, 60, 277-300.
11. Jiang Z, Chu PG, Woda BA, et al (2006). Analysis of RNAbinding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol, 7, 556-64.
12. Liu XH, Rose DP (1996). Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res, 56, 5125-7.
13. Mittal A, Poudel B, Pandeya DR, et al (2012). Serum amyloid a as an independent prognostic factor for renal cell carcinoma- -a hospital based study from the Western region of Nepal. Asian Pac J Cancer Prev, 13, 2253-5.
14. Motzer RJ, Bander NH, Nanus DM (1996). Renal-cell carcinoma. N Engl J Med, 335, 865-75.
15. Nogueira M, Kim HL (2008). Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol, 26, 113-24.
16. Patel C, Ahmed A, Ellsworth P (2012). Renal cell carcinoma: a reappraisal. Urol Nurs, 32, 182-90; quiz 91.
17. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M (1997). Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res, 57, 1276-80.
18. Saussez S, Cucu DR, Decaestecker C, et al (2006). Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol, 13, 999-1009.
19. Schmittgen TD, Livak KJ (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc, 3, 1101-8.
20. Sejima T,Miyagawa I (2006). Significance of Fas expression alteration during tumor progression of renal cell carcinoma. Int J Urol, 13, 257-64.
21. Shindo T, Masumori N, Kobayashi K, et al (2013). Long-term outcome of small, organ-confined renal cell carcinoma (RCC) is not always favourable. BJU Int, 111, 941-5.
22. Shvarts O, Seligson D, Lam J, et al (2005). p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol, 173, 725-8.
23. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29.
24. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF (1971). Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer, 28, 1165-77.
25. Skolarikos A, Alivizatos G, Bamias A, et al (2005). Bcl-2 protein and DNA ploidy in renal cell carcinoma: do they affect patient prognosis?. Int J Urol, 12, 563-9.
26. Tatokoro M, Fujii Y, Kawakami S, et al (2011). Phase-II trial of combination treatment of interferon-alpha, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci, 102, 137-43.
27. Tostain J, Li G, Gentil-Perret A,Gigante M (2010). Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur J Cancer, 46, 3141-8.
28. Tsuchiya A, Sakamoto M, Yasuda J, et al (2003). Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol, 163, 2503-12.
29. Wei C, Lai YQ, Li XX,Ye JX (2013a). TGF-beta-activated kinase-1: a potential prognostic marker for clear cell renal cell carcinoma. Asian Pac J Cancer Prev, 14, 315-20.
30. Wood CG (2006). Molecular markers of prognosis in renal cell carcinoma: Insight into tumor biology helps define risk and provides targets for therapy. J Surg Oncol, 94, 264-5.